Clinical Trials
3
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (66.7%)Phase 1
1 (33.3%)IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor
Phase 1
Terminated
- Conditions
- Cholangiocarcinoma With IDH1 MutationSolid Tumors With IDH1 Mutation
- Interventions
- Drug: AB-218 capsule
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- AnHeart Therapeutics Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05814536
- Locations
- 🇨🇳
Beijing Jishuitan Hospital, Beijing, Beijing, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- AnHeart Therapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04617054
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- AnHeart Therapeutics Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT04395677
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
News
No news found